• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Celularity Inc.

    2/13/23 5:12:00 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CELU alert in real time by email
    SC 13G 1 c61044150.htm SCHEDULE 13G


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.  )*


    Celularity Inc.
    (Name of Issuer)

    Class A Common Stock
    (Title of Class of Securities)

    151190105
    (CUSIP Number)


    December 31, 2022
    (Date of Event which Requires Filing
    of this Statement)



    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [   ]     Rule 13d-1(b)
    [X]     Rule 13d-1(c)
    [   ]     Rule 13d-1(d)



    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 151190105
     
    13G
    Page 2 of 5 Pages
    1
    NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
     
    C.V. Starr & Co., Inc.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)  ☐
    (b)  ☐
     
    3
    SEC USE ONLY


    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Nevada
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED
    BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    7,640,693
     
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    7,640,693
     
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    7,640,693
     
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES            ☐
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.27%
    12
    TYPE OF REPORTING PERSON*
     
    CO


    Item 1(a)
    Name of Issuer:
       
     
    Celularity Inc. (formerly known as GX Acquisition Corp.) (the “Issuer”)
       
    Item 1(b)
    Address of Issuer's Principal Executive Offices:
       
     
    170 Park Ave
     
    Florham Park, NJ 07932
       
    Item 2(a)
    Name of Person Filing:
       
     
    The information required by Item 2(a) is set forth in Row 1 of the cover page hereto for the Reporting Person and is incorporated herein by reference for the Reporting Person.
       
    Item 2(b)
    Address of Principal Business Office or, if none, Residence:
       

     399 Park Ave, 8th Floor,
    New York, New York 10022
       
    Item 2(c)
    Citizenship:
       
     
    The information required by Item 2(c) is set forth in Row 4 of the cover page hereto for the Reporting Person and is incorporated herein by reference for the Reporting Person.
       
    Item 2(d)
    Title of Class of Securities:
       
     
    Class A Common Stock, $0.0001 par value per share (“Class A Common Stock”)
       
    Item 2(e)
    CUSIP Number:
       
     
    151190105
       
    Item 3
    Statement filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c):
       
     
    The information required by Item 3 is set forth in Row 12 of the cover page hereto for the Reporting Person and is incorporated herein by reference for the Reporting Person.



    Item 4
    Ownership:
       
     
    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page hereto for the Reporting Person and is incorporated herein by reference for the Reporting Person.
       
     
    The Issuer’s securities reported on this Schedule 13G are comprised of 7,640,693 shares of Class A Common Stock.
       
     
    The ownership percentage disclosed in Row 11 of the cover page hereto is based on 145,013,313 outstanding shares of Class A Common Stock, as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 10, 2022.
       
    Item 5
    Ownership of Five Percent or Less of a Class:
       
     
    Not Applicable
       
    Item 6
    Ownership of More than Five Percent on Behalf of Another Person:
       
     
    Not Applicable
       
    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security
    Being Reported on By the Parent Holding Company or Control Person:
       
     
    Not Applicable
       
    Item 8
    Identification and Classification of Members of the Group:
       
     
    Not Applicable
       
    Item 9
    Notice of Dissolution of Group:
       
     
    Not Applicable
       
    Item 10
    Certification:
       
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    [Remainder of page intentionally left blank]


    SIGNATURE

    After reasonable inquiry and to the best of the knowledge and belief of the undersigned, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated:  February 13, 2023

     
    C.V. STARR & COMPANY, INC.
       
     
    By:
    /s/ Howard I. Smith
       
    Name: Howard I. Smith
       
    Title: Vice Chairman - Finance

    Get the next $CELU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CELU

    DatePrice TargetRatingAnalyst
    1/30/2023$5.00 → $1.00Equal-Weight → Underweight
    Morgan Stanley
    12/22/2022Outperform → Perform
    Oppenheimer
    6/22/2022$15.00Buy
    H.C. Wainwright
    4/6/2022$10.00Buy → Hold
    Truist
    1/28/2022$9.00Outperform
    Oppenheimer
    11/24/2021$9.00Equal-Weight
    Morgan Stanley
    10/19/2021$12.00Buy
    Truist Securities
    More analyst ratings

    $CELU
    SEC Filings

    View All

    Celularity Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Celularity Inc (0001752828) (Filer)

    6/3/26 5:22:06 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Celularity Inc (0001752828) (Filer)

    5/28/26 4:54:19 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-Q filed by Celularity Inc.

    NT 10-Q - Celularity Inc (0001752828) (Filer)

    5/15/26 4:30:21 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

    FLORHAM PARK, N.J. and ORLANDO, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, and Fountain Life Management, LLC ("Fountain Life"), a leading healthy longevity company delivering a next-generation preventive health model through advanced diagnostics, restorative therapeutics, and AI-driven health intelligence, today announced the availability of cenplacel-L, a placental-derived allogeneic investigational cell therapy, for investigational use by licensed physicians in the State of Florida under recently enacted legislation supporting responsi

    6/4/26 8:00:00 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity Releases CEO Letter to Shareholders

    FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today announced that it has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Celularity's Founder, Chairman, and Chief Executive Officer, to the Investor Relations section of its website. The letter is also included below. Dear Fellow Shareholders, I want to take this opportunity to provide an important update on the developments at Celularity over the past several months particularly in the context of evolving clinical and regulatory progress.

    6/3/26 4:15:00 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity Appoints Rick Gonzalez as Chief Commercial Officer

    FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular and regenerative therapies, today announced the appointment of Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026. In this role, Mr. Gonzalez will oversee global commercial strategy and execution for cenplacel-L, Lifebank and the Company's broader regenerative medicine portfolio, and will report to Robert J. Hariri, M.D., Ph.D., Celularity's Chairman, Chief Executive Officer and Founder. "Rick's appointment comes at an important time for Celularity as we conti

    6/3/26 8:00:00 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Celularity downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Celularity from Equal-Weight to Underweight and set a new price target of $1.00 from $5.00 previously

    1/30/23 7:11:17 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity downgraded by Oppenheimer

    Oppenheimer downgraded Celularity from Outperform to Perform

    12/22/22 7:40:17 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Celularity with a new price target

    H.C. Wainwright initiated coverage of Celularity with a rating of Buy and set a new price target of $15.00

    6/22/22 7:19:25 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lim Kok Thay bought $5,331,335 worth of shares (21,410,983 units at $0.25) (SEC Form 4)

    4 - Celularity Inc (0001752828) (Issuer)

    1/17/24 5:22:20 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hariri Robert J bought $2,984,294 worth of shares (18,422,124 units at $0.16), increasing direct ownership by 182% to 28,570,434 units (SEC Form 4)

    4 - Celularity Inc (0001752828) (Issuer)

    10/10/23 9:48:11 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Barach Philip Alan

    3 - Celularity Inc (0001752828) (Issuer)

    4/24/26 6:41:27 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Barach Daniele Wolf

    3 - Celularity Inc (0001752828) (Issuer)

    4/24/26 6:41:04 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Philip & Daniele Barach Family Trust

    3 - Celularity Inc (0001752828) (Issuer)

    4/24/26 6:40:13 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Leadership Updates

    Live Leadership Updates

    View All

    Celularity Appoints Rick Gonzalez as Chief Commercial Officer

    FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular and regenerative therapies, today announced the appointment of Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026. In this role, Mr. Gonzalez will oversee global commercial strategy and execution for cenplacel-L, Lifebank and the Company's broader regenerative medicine portfolio, and will report to Robert J. Hariri, M.D., Ph.D., Celularity's Chairman, Chief Executive Officer and Founder. "Rick's appointment comes at an important time for Celularity as we conti

    6/3/26 8:00:00 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NEXGEL Appoints Ian Blackman as Chief Financial Officer

    Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Ian Blackman, CPA, as Chief Financial Officer. Mr. Blackman will help to advance the closing of the definitive agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity Inc., ("Celularity")

    4/27/26 9:00:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

    3/10/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $CELU
    Financials

    Live finance-specific insights

    View All

    Celularity Provides Corporate Update

    FLORHAM PARK, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, has issued a Corporate Update to Shareholders from Robert J. Hariri, M.D., Ph.D., Founder, Chairman, and CEO. Dear Shareholders, I am pleased to share recent developments at Celularity, including an update on our commercial-stage advanced biomaterial products business. Let me start by reiterating what we said in our announcement last week, which is that we are resolutely committed to regaining full compliance with Nasdaq's listing requirements. We acknowledge the importance of timely filings and have been diligently working with our new auditi

    10/22/24 8:30:00 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Celularity Inc. (Amendment)

    SC 13D/A - Celularity Inc (0001752828) (Subject)

    3/15/24 5:32:04 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Celularity Inc. (Amendment)

    SC 13G/A - Celularity Inc (0001752828) (Subject)

    2/8/24 6:00:11 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Celularity Inc. (Amendment)

    SC 13D/A - Celularity Inc (0001752828) (Subject)

    1/17/24 5:15:41 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care